Literature DB >> 2673218

Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

R Fears1.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2673218      PMCID： PMC1138828          DOI： 10.1042/bj2610313

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


× No keyword cloud information.
  90 in total

1.  Plasminogen activation by tissue plasminogen activator in the presence of stimulating CNBr fragment FCB-2 of fibrinogen is a two-phase reaction. Kinetic analysis of the initial phase of slow plasmin formation.

Authors:  R Beckmann; M Geiger; B R Binder
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

Review 2.  Reperfusion therapy of acute myocardial infarction.

Authors:  W W O'Neill; E J Topol; B Pitt
Journal:  Prog Cardiovasc Dis       Date:  1988 Jan-Feb       Impact factor: 8.194

3.  The FDA Advisory Panel's decision on rt-PA.

Authors:  S Sherry
Journal:  J Clin Pharmacol       Date:  1987-10       Impact factor: 3.126

4.  Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator.

Authors:  W Nieuwenhuizen; A Vermond; M Voskuilen; D W Traas; J H Verheijen
Journal:  Biochim Biophys Acta       Date:  1983-10-17

5.  The binding of human plasminogen to fibrin and fibrinogen.

Authors:  M A Lucas; L J Fretto; P A McKee
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

6.  The binding of plasminogen to fibrin: evidence for plasminogen-bridging.

Authors:  A J Garman; R A Smith
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

7.  Morphology of bovine fibrinogen monomers and fibrin oligomers.

Authors:  R C Williams
Journal:  J Mol Biol       Date:  1981-08-15       Impact factor: 5.469

8.  Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.

Authors:  D Gheysen; H R Lijnen; L Piérard; F de Foresta; E Demarsin; P Jacobs; M De Wilde; A Bollen; D Collen
Journal:  J Biol Chem       Date:  1987-08-25       Impact factor: 5.157

9.  Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin.

Authors:  R A Bok; W F Mangel
Journal:  Biochemistry       Date:  1985-06-18       Impact factor: 3.162

10.  Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator.

Authors:  E Suenson; L C Petersen
Journal:  Biochim Biophys Acta       Date:  1986-04-22
View more
  5 in total

1.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Inner clot diffusion and permeation during fibrinolysis.

Authors:  S L Diamond; S Anand
Journal:  Biophys J       Date:  1993-12       Impact factor: 4.033

3.  Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.

Authors:  P K Anonick; S L Gonias
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

4.  Stimulation of plasmin activity by oleic acid.

Authors:  A A Higazi; Z Finci-Yeheskel; A A Samara; R Aziza; M Mayer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

5.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.